A new investment option for the Hadassah Medical Center’s biotechnology innovations recently became available with the Hadasit Bio-Holdings Ltd (HBL)’s approval by the United States Securities & Exchange Commission (SEC) to trade as an American Depository Receipt (ADR), sponsored by Bank of New York-Mellon. This permits the purchase of HBL stocks on the Tel Aviv Stock Exchange through a local broker or online. HBL’s portfolio is all based on intellectual property developed and owned by Hadassah University Medical Center.
“Israel is known as the ‘start-up nation’ and we are very excited to offer U.S. investors access to a promising group of Israeli biomedical startups,” commented Ophir Shahaf, Chief Executive Officer of HBL. “By establishing Hadasit Bio-Holdings, we have the opportunity to select the most promising biotechnology companies, many of which have already exhibited promising clinical results with strategic partnerships and major investments from companies like Sanofi-Aventis, Teva, and Biotime.” Mr. Shahaf adds: “Through its unique link to the Hadassah University Hospital, responsible for the majority of Israel’s hospital-based translational research, Hadasit invests in promising companies that address unmet life science needs.”
The companies comprising Hadasit’s portfolio exhibit leadership in three major medical areas: Oncology (Therapeutics and Diagnostics), Neurodegenerative disorders (including cell-based therapeutics for Graft-Versus-Host Disease, Age-Related Macular Degeneration, and Multiple Sclerosis), and Inflammatory Disorders (Rheumatoid Arthritis and Irritable Bowel Syndrome). For additional information on Hadasit Bio-Holding’s ADR program, e-mail hadasit@kcsa.com.
